KR102704978B1 - 면역 장애의 치료 - Google Patents

면역 장애의 치료 Download PDF

Info

Publication number
KR102704978B1
KR102704978B1 KR1020237007387A KR20237007387A KR102704978B1 KR 102704978 B1 KR102704978 B1 KR 102704978B1 KR 1020237007387 A KR1020237007387 A KR 1020237007387A KR 20237007387 A KR20237007387 A KR 20237007387A KR 102704978 B1 KR102704978 B1 KR 102704978B1
Authority
KR
South Korea
Prior art keywords
cells
ang1
subject
stem cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237007387A
Other languages
English (en)
Korean (ko)
Other versions
KR20230038590A (ko
Inventor
실비우 이테스쿠
폴 시몬스
Original Assignee
메조블라스트 인터내셔널 에스에이알엘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53385603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102704978(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en
Application filed by 메조블라스트 인터내셔널 에스에이알엘 filed Critical 메조블라스트 인터내셔널 에스에이알엘
Priority to KR1020247029823A priority Critical patent/KR102865313B1/ko
Publication of KR20230038590A publication Critical patent/KR20230038590A/ko
Application granted granted Critical
Publication of KR102704978B1 publication Critical patent/KR102704978B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
KR1020237007387A 2014-06-10 2015-06-01 면역 장애의 치료 Active KR102704978B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247029823A KR102865313B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2014902194A AU2014902194A0 (en) 2014-06-10 Treatment of immune disorders
AUAU2014902194 2014-06-10
AUAU2014902257 2014-06-13
AU2014902257A AU2014902257A0 (en) 2014-06-13 Treatment of immune disorders 2
KR1020177000032A KR20170007854A (ko) 2014-06-10 2015-06-01 면역 장애의 치료
PCT/EP2015/062138 WO2015189063A1 (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177000032A Division KR20170007854A (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029823A Division KR102865313B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Publications (2)

Publication Number Publication Date
KR20230038590A KR20230038590A (ko) 2023-03-20
KR102704978B1 true KR102704978B1 (ko) 2024-09-09

Family

ID=53385603

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020237007387A Active KR102704978B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020257031878A Pending KR20250143870A (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020247029823A Active KR102865313B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020177000032A Ceased KR20170007854A (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257031878A Pending KR20250143870A (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020247029823A Active KR102865313B1 (ko) 2014-06-10 2015-06-01 면역 장애의 치료
KR1020177000032A Ceased KR20170007854A (ko) 2014-06-10 2015-06-01 면역 장애의 치료

Country Status (9)

Country Link
US (4) US10624930B2 (enExample)
EP (2) EP4137146A1 (enExample)
JP (5) JP6800757B2 (enExample)
KR (4) KR102704978B1 (enExample)
CN (2) CN114129598A (enExample)
AU (2) AU2015273799B2 (enExample)
CA (1) CA2950804C (enExample)
SG (1) SG11201609993YA (enExample)
WO (1) WO2015189063A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
EP2714057B1 (en) * 2011-06-03 2019-11-06 Mesoblast, Inc. Methods of treating or preventing neurological diseases
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
CN106929474B (zh) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 一种m2巨噬细胞诱导剂
AU2018243554C1 (en) * 2017-03-31 2025-01-30 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
EP3716988A4 (en) 2017-11-29 2021-12-15 Figene, LLC INTERACTION OF FIBROBLASTS AND IMMUNE CELLS FOR THE ACTIVATION AND USE THEREOF
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用
EP4630018A1 (en) * 2022-12-09 2025-10-15 Mesoblast International Sàrl Method of treating inflammation with cellular compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
CA2564679C (en) * 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
WO2010005527A1 (en) * 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
WO2010059828A1 (en) * 2008-11-19 2010-05-27 Anthrogenesis Corporation Amnion derived adherent cells
JP5678360B2 (ja) * 2009-09-28 2015-03-04 株式会社ジーシー 間葉系幹細胞の培養方法
US20140017787A1 (en) * 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
PL2785359T3 (pl) * 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
CN102899293A (zh) 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
KR102577698B1 (ko) * 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hye Jin Jin et al. Comparative Analysis of Human Mesenchymal Stem Cells from Bone Marrow. Int. J. Mol. Sci, v14(9), pp.17986-18001 (2013.09.03.).
Matthew B Murphy et al. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental & Molecular Medicine, v.45, e54 pp.1-16 (2013.11.15.).

Also Published As

Publication number Publication date
US12257270B2 (en) 2025-03-25
AU2020244403A1 (en) 2020-10-29
SG11201609993YA (en) 2016-12-29
US20170106023A1 (en) 2017-04-20
JP2025109787A (ja) 2025-07-25
US12616722B2 (en) 2026-05-05
JP6800757B2 (ja) 2020-12-16
JP2021028337A (ja) 2021-02-25
CN114129598A (zh) 2022-03-04
EP3154565A1 (en) 2017-04-19
AU2020244403B2 (en) 2024-03-07
US20230141347A1 (en) 2023-05-11
JP7009594B2 (ja) 2022-02-10
KR102865313B1 (ko) 2025-09-29
EP4137146A1 (en) 2023-02-22
CA2950804C (en) 2023-08-22
CN106659743B (zh) 2022-03-01
CN106659743A (zh) 2017-05-10
CA2950804A1 (en) 2015-12-17
US20200281984A1 (en) 2020-09-10
AU2015273799A1 (en) 2016-12-15
JP2023090901A (ja) 2023-06-29
KR20240135079A (ko) 2024-09-10
KR20230038590A (ko) 2023-03-20
US20250319134A1 (en) 2025-10-16
US10624930B2 (en) 2020-04-21
JP2017526619A (ja) 2017-09-14
KR20170007854A (ko) 2017-01-20
AU2015273799B2 (en) 2020-07-02
EP3154565B1 (en) 2023-05-03
KR20250143870A (ko) 2025-10-02
JP7680493B2 (ja) 2025-05-20
JP7279212B2 (ja) 2023-05-22
WO2015189063A1 (en) 2015-12-17
HK1231386A1 (en) 2017-12-22
US11406669B2 (en) 2022-08-09
JP2022040254A (ja) 2022-03-10

Similar Documents

Publication Publication Date Title
US12616722B2 (en) Treatment of immune disorders
AU2022200640B2 (en) Improved stem cell composition
HK40088295A (en) Treatment of immune disorders
HK1231386B (en) Treatment of immune disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230302

Application number text: 1020177000032

Filing date: 20170102

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230720

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240617

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240904

Application number text: 1020177000032

Filing date: 20170102

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240904

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240905

End annual number: 3

Start annual number: 1

PG1601 Publication of registration